5 completed, 1 terminated. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow OOS-A regimen: new trials by email Literature Review of OOS-A regimen trials Research Report on OOS-A regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010 Regimen A, Regimen B, Regimen C - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Pearl Therapeutics, Inc. | 56 | 2017-10-17 | 2020-06-11 |
| Multi-centre Failed Bowel Prep RCT 4L PegLyte + 15 mg bisacodyl, 6L PegLyte + 15 mg bisacodyl - Colonoscopy, Bowel Preparation | Phase 3 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 196 | 2017-02-13 | 2020-02-21 |
| A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route OZ439 120mg PIB, 120 mg OZ439 caplet, 120mg OZ439 caplet via Enterion capsule - Healthy Volunteers | Phase 1 | Completed | Medicines for Malaria Venture | 11 | 2012-11-01 | 2015-03-06 |
| An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor Regimen A, Regimen B, Regimen C - Cancer | Phase 1 | Completed | GlaxoSmithKline | 28 | 2010-10-21 | 2017-11-14 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3) Regimen A, Regimen B, Regimen C - Hematological Malignancies | Phase 2 | Terminated | Medical University of South Carolina | 78 | 2010-06-01 | 2018-07-11 |
| Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma Regimen A, Regimen B - Lymphoma | Phase 2 | Completed | Northwestern University | 25 | 2007-02-06 | 2019-10-15 |
Burkitt Lymphoma (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Neoplasms (1) · Pulmonary Disease, Chronic Obstructive (1)
GlaxoSmithKline (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Medical University of South Carolina (1) · Medicines for Malaria Venture (1) · Northwestern University (1) · Pearl Therapeutics, Inc. (1)
United States (4) · Canada (1) · United Kingdom (1)
Fiona Macintyre, PhD (1) · Leo Gordon, MD (1) · Michael Sey, MD (1) · Paul M. Dorinsky, MD (1) · Robert Stuart, MD (1)
PMID 23608920, PMID 24146219, PMID 31289092, PMID 32253054, PMID 34256147
P30CA060553 (1)